161 related articles for article (PubMed ID: 3122489)
1. Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies.
Boccadoro M; Durie BG; Frutiger Y; Gavarotti P; Redoglia V; Massaia M; D'Alberto M; Marmont F; Gallamini A; Tribalto M
Acta Haematol; 1987; 78(4):239-42. PubMed ID: 3122489
[TBL] [Abstract][Full Text] [Related]
2. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
[TBL] [Abstract][Full Text] [Related]
3. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
[TBL] [Abstract][Full Text] [Related]
4. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
Lokhorst HM; Boom SE; Terpstra W; Roholl P; Gerdes J; Bast BJ
Br J Haematol; 1988 Aug; 69(4):477-81. PubMed ID: 3044442
[TBL] [Abstract][Full Text] [Related]
5. Serum neopterin and beta 2-microglobulin concentrations in monoclonal gammopathies.
Fine JM; Lambin P; Desjobert H
Acta Med Scand; 1988; 224(2):179-82. PubMed ID: 3048055
[TBL] [Abstract][Full Text] [Related]
6. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.
Luoni R; Ucci G; Riccardi A; Gobbi P; Avato FM; Vignale C; Ascari E
Cancer; 1992 Mar; 69(6):1368-72. PubMed ID: 1540874
[TBL] [Abstract][Full Text] [Related]
7. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
8. Ploidy and proliferative characteristics in monoclonal gammopathies.
Latreille J; Barlogie B; Johnston D; Drewinko B; Alexanian R
Blood; 1982 Jan; 59(1):43-51. PubMed ID: 6172171
[TBL] [Abstract][Full Text] [Related]
9. Serum beta 2-microglobulin, serum creatinine and bone marrow plasma cells in benign and malignant monoclonal gammopathy.
Morell A; Riesen W
Acta Haematol; 1980; 64(2):87-93. PubMed ID: 6159767
[TBL] [Abstract][Full Text] [Related]
10. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma.
Bartl R; Frisch B; Diem H; Mündel M; Nagel D; Lamerz R; Fateh-Moghadam A
Cancer; 1991 Nov; 68(10):2241-50. PubMed ID: 1913461
[TBL] [Abstract][Full Text] [Related]
11. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.
Boccadoro M; Gallamini A; Fruttero A; Gavarotti P; Redoglia V; Buffa F; Ruá S; Pileri A
J Clin Oncol; 1985 Nov; 3(11):1503-7. PubMed ID: 4056842
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase.
Schambeck CM; Wick M; Bartl R; Lamerz R; Fateh-Moghadam A
J Clin Pathol; 1995 May; 48(5):477-81. PubMed ID: 7629298
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
17. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of plasma cell infiltrates in the bone marrow. A clinicopathological study on 80 patients including immunohistochemistry and morphometry.
Thiele J; Arenz B; Klein H; Vierbuchen M; Zankovich R; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1988; 412(6):553-62. PubMed ID: 3129867
[TBL] [Abstract][Full Text] [Related]
20. Cytobiological studies in multiple myeloma.
Pileri A; Massaia M; Dianzani U; Omedè P; Boccadoro M
Acta Haematol; 1987; 78 Suppl 1():41-2. PubMed ID: 2829488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
